ExploreWatchlistsPricing
  1. JP-listed companies
  2. PeptiDream Inc.
  3. Financials
  4. Accounts receivable, net

PeptiDream Inc. (4587)

Market cap
¥153.7B
P/E ratio
Peptidream develops new drugs using its proprietary PDPS platform and creates radiopharmaceuticals for diagnosing and treating cancer and other diseases.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndAccounts receivable, net (Million JPY)YoY (%)
Dec 31, 20255,867+11.06%
Dec 31, 20245,283+6.28%
Dec 31, 20234,971-70.04%
Dec 31, 202216,589+1945.28%
Dec 31, 2021811-89.23%
Dec 31, 20207,531

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat